AF
DMAC icon

Allworth Financial’s DiaMedica Therapeutics DMAC Stock Holding History

Allworth Financial’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$55.4K Buy
8,189
+8,088
+8,008% +$64.1K ﹤0.01% 2243
2025
Q4 		$804 Buy
101
+16
+19% +$120 ﹤0.01% 4419
2025
Q3 		$584 Buy
+85
New +$461 ﹤0.01% 4395

Other funds holding DMAC

CLG
Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Allworth Financial's DMAC Position: Q1 2026 in Review

Allworth Financial increased its DiaMedica Therapeutics (DMAC) stake by 8,008% in Q1 2026, buying an estimated $64.1K and bringing the position to 8,189 shares worth $55.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2243.

Allworth Financial first reported a position in DMAC in Q3 2025 and has held it in 3 quarters since. 98 funds tracked by Wall St. Rank hold DMAC as of Q1 2026.

  • Allworth Financial held 8,189 shares of DiaMedica Therapeutics worth $55.4K as of Q1 2026.
  • Allworth Financial bought 8,088 DiaMedica Therapeutics shares in Q1 2026, an estimated $64.1K.
  • DiaMedica Therapeutics made up ﹤0.01% of Allworth Financial's portfolio in Q1 2026, its #2243 holding.
  • Allworth Financial first reported a position in DiaMedica Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 98 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q1 2026.

Based on Allworth Financial's 13F filing for Q1 2026, filed 15 May 2026.